Q1 FY27 earnings call · July 24, 2026

Jubilant Ingrevia Ltd (JUBLINGREA) Q1 FY27 Earnings Call: Revenue at Rs.1,300 Cr, Pipeline Potential at Rs.3,500 Cr

Cofacto ResearchPublished July 24, 20265 min read
Quick summary

Jubilant Ingrevia Ltd held its Q1 FY27 earnings call on July 22, 2026. Here's a quick read of what management said — performance, strategy, and the outlook ahead.

Jubilant Ingrevia Posts 15-Quarter High Revenue of Rs.1,300 Cr

  • Revenue of Rs.1,300 crore — a 15-quarter high in Q1 FY 2026-2027, up 25% YoY, driven by pharma, nutrition, and agrochemicals demand.
  • EBITDA of Rs.209 crore — up 36% YoY and 22% QoQ, with margin improvement on richer product mix in CDMO & fine chemicals.
  • PAT of Rs.106 crore — up 41% YoY and 22% QoQ, reflecting operating leverage and portfolio mix benefits.
  • Specialty Chemicals EBITDA of Rs.139 crore — on revenue of Rs.533 crore (+11% YoY), with margin at 26% supported by CDMO and fine chemicals.
  • Nutrition & Health EBITDA of Rs.36 crore — highest in three years, margin 15% on revenue of Rs.243 crore (+36% YoY).
  • Chemical Intermediates EBITDA surged 240% YoY to Rs.57 crore on revenue of Rs.524 crore (+38% YoY), driven by robust demand and price escalations.

Pipeline Crosses 100+ Molecules with Rs.3,500+ Cr Peak Revenue Potential

  • 100+ molecules in CDMO & fine chemicals pipeline — representing Rs.3,500+ crore peak revenue potential; 25+ molecules confirmed and 5 new molecules added in Q1 FY 2026-2027 across pharma, semicon, and personal care.
  • Confirmed molecule order book of Rs.1,500+ crore — includes a large CDMO agro contract; expected to contribute ~25% of specialty and nutrition portfolio revenue in FY 2026-2027.
  • CDMO project count expanded from 20 to 25 — management has not yet updated the Rs.1,500 crore peak revenue figure due to the early stage of new molecules.
  • 15+ new molecules won in FY 2025-2026 — several entering their second year in FY 2026-2027; management anticipates higher volumes as Western customers provide volume indications by August/September and confirmations by October.
  • Top-of-funnel opportunities at 100+ — recent US customer meetings generated at least 10 new opportunities not yet reflected in the prior quarter's pipeline.
  • "Full protection" on the $300 million CDMO contract — management confirmed a take-or-pay commitment spanning five years, which will "more than cover communicated expectations" even if volumes do not materialise.

Nutrition and Chemical Intermediates Lead Growth; Specialty Mix Improves

  • Nutrition & Health revenue grew 36% YoY to Rs.243 crore in Q1 FY 2026-2027, with EBITDA of Rs.36 crore at a 15% margin — the highest in three years.
  • Chemical Intermediates revenue jumped 38% YoY to Rs.524 crore; EBITDA of Rs.57 crore represented a 240% YoY increase, contributing ~Rs.40 crore of the consolidated EBITDA YoY gain.
  • Specialty Chemicals revenue rose 11% YoY to Rs.533 crore; EBITDA of Rs.139 crore was up 7% YoY, driven by volume growth, product mix improvement, and price acceleration in Q1 FY 2026-2027.
  • Fine chemicals showed strong volume and pricing, though sequential comparison to Q4 FY 2025-2026 is not reflective due to the peak quarter effect; on a like-to-like YoY basis, revenue grew 11%.
  • Agrochemicals demand showed recovery signs with export visibility and price increases; management noted slow but expected bounce-back in coming quarters of FY 2026-2027.
  • Electronics/semicon customers — strong traction with integrated opportunities was highlighted as a growth vector by management.

Full-Year EBITDA Guidance Maintained at Rs.750–800 Cr Despite H2 Acetyl Risk

  • Full-year FY 2026-2027 EBITDA guidance maintained at Rs.750–800 crore — management flagged potential downside risk from acetyl segment volatility in H2 FY 2026-2027 despite expected sequential improvement.
  • H1 FY 2026-2027 EBITDA expected at Rs.400+ crore — roughly Rs.200 crore per quarter; specialty & nutrition segments drive 70–80% of EBITDA mix, with chemical intermediates contributing ~Rs.100 crore.
  • Sequential revenue and EBITDA improvement expected over the remaining quarters of FY 2026-2027, led by specialty chemicals, nutrition, and acetyl recovery.
  • Q2 volumes for a large CDMO contract expected to exceed Q1 levels — quarterly phasing remains dynamic; clarity from the customer on Q3 FY 2026-2027 is expected within the next month.
  • Targeting Rs.100 crore lean savings in FY 2026-2027 — completed integration of Jubilant Pharmova; actively evaluating growth opportunities in electronics, semiconductors, cosmetics, and nutrition.
  • B3 pricing may start to decline by end of Q2 FY 2026-2027 based on historical trends; mitigation actions include increasing the mix of high-value food/pharma/cosmetic grade products and ongoing cost improvement.

New Multipurpose Plant On Track; Pyridine Utilisation at 95%+

  • New multipurpose plant on track for commissioning by end of calendar year 2026 (within FY 2026-2027), supporting CDMO/fine chemicals strategy.
  • Pyridine plant utilisation at 95%+ in Q1 FY 2026-2027 with strong volume momentum; pricing pressure exists in commoditised base pyridine due to China overcapacity, but downstream derivatives and picoline pricing is holding up.
  • Human-grade nutrition plant with 5,000 tons annual capacity operating at 50% run rate for Niacin and Niacinamide cosmetic grade; targeting 70%+ by end of FY 2026-2027.
  • New vinyl pyridine plant at 50%+ utilisation — expected to reach 70% soon; acetates business benefiting from oil price escalations.
  • Captive consumption of pyridine and picoline increasing — driven by higher B3 volumes and new derivatives/CDMO contracts, improving vertical integration benefits.

Geopolitical Uncertainty and Acetyl Volatility Pose H2 Risks

  • Geopolitical uncertainties in the Middle East continue to impact power and fuel expenses, which rose in Q1 FY 2026-2027 due to higher volume and increased fuel costs (LSHS/natural gas) linked to the Gulf crisis.
  • Acetyl segment volatility flagged as a potential downside risk to H2 FY 2026-2027 EBITDA, despite the maintained full-year guidance of Rs.750–800 crore.
  • B3 pricing may decline by end of Q2 FY 2026-2027 based on historical trends; Q3 FY 2026-2027 could see an impact, though management has mitigation actions including product mix improvement and cost reduction.
  • Pricing pressure in commoditised base pyridine due to China overcapacity, though downstream derivatives and picoline pricing is holding up.
  • Other expenses increased mainly from higher logistics costs, which were successfully passed on to customers in Q1 FY 2026-2027.
  • Raw material inventory risk from Q1 FY 2026-2027 has been managed effectively; finished good prices have not declined as feared and are now trending up in some segments.

Ask about this

Ask Cofacto a question about this call. Answers cite filings and company data.

Companies on this page

Related

Share on X · LinkedIn · WhatsApp

Disclaimer: This earnings call summary is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.